CD BioSciences has announced the launch of its high-quality, cost-effective C. elegans pharyngeal pumping analysis services for drug screening. Utilizing the model organism C. elegans, the company aims to deliver reliable results for pharmaceutical companies looking to expedite their drug discovery processes.
C. elegans serves as an excellent model organism for toxicology studies and drug discovery due to its behavior, such as pharyngeal pumping, which can be visually scored. This behavior is controlled by environmental cues that activate sensory and neural signals to coordinate pharyngeal activity, making it an invaluable biological test for screening chemical modulation.
CD BioSciences brings extensive expertise in C. elegans research to this service. By monitoring and analyzing changes in pharyngeal pumping patterns, the company aids researchers in quickly and effectively screening potential drug candidates for both efficacy and toxicity. Beyond C. elegans pharyngeal pumping analysis, CD BioSciences also offers drug screening services based on its Drosophila in vivo screening platform, which includes model building, phenotypic data collection, screens, and pathway prediction. This platform is complemented by productive products such as recombinant drosophila proteins, antibodies, and media.
"We have flexible, rapid, and cost-effective drug screening analysis services and products to help our clients identify new potentially effective compounds and novel targets," stated a spokesperson for CD BioSciences. "By leveraging our unique capabilities with C. elegans and Drosophila, we can provide valuable insights into the effects of potential drug candidates, helping our clients make informed decisions and accelerate the drug discovery process."
The company’s team of experts is committed to providing comprehensive drug screening services and related products, employing cutting-edge techniques to ensure accurate and reproducible results. With a proven track record of helping pharmaceutical companies optimize their drug discovery projects, CD BioSciences is well-positioned to drive the industry forward with its innovative approach to drug screening.
